Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline

融资将支持RN-014和RN-032的开发，并持续扩大公司在肾脏疾病领域的产品管线

KYOTO, Japan

日本京都

,

，

July 21, 2026

2026年7月21日

/PRNewswire/ -- Rege Nephro Co., Ltd. ('Rege Nephro'), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately

/美通社/ -- 专注于基于iPS细胞的肾脏再生医学和药物发现的临床阶段生物技术公司Rege Nephro有限公司（“Rege Nephro”）今日宣布完成一轮总额约为

US$10.6 million

1060万美元

through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to support commercialization activities for RN-014, the company's lead candidate for autosomal dominant polycystic kidney disease (ADPKD), advance its iPS cell-derived regenerative medicine program RN-032, and fund continued research and development activities.

通过发行J-KISS（日本简易证券）股份收购权。所得资金预计将用于支持公司针对常染色体显性多囊肾病（ADPKD）的主要候选药物RN-014的商业化活动，推进其源自诱导多能干细胞（iPS细胞）的再生医学项目RN-032，并为持续的研发活动提供资金。

The financing is intended to support the company's growth through its anticipated Series C financing and beyond..

此次融资旨在支持公司通过预期的C轮融资及后续阶段实现增长。

Continue Reading

继续阅读

Background of the Funding

资助背景

Rege Nephro is dedicated to developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options.

Rege Nephro 致力于为目前治疗选择有限的肾病患者开发创新疗法和医疗技术。

The company's lead program, RN-014, recently reached LPLV (Last Patient Last Visit) in its Phase 2a clinical trial, marking an important milestone. RN-014 is a small-molecule therapeutic candidate identified through screening using an iPS cell-derived ADPKD disease model, and analysis of Phase 2a clinical trial data is currently underway..

公司的领先项目RN-014最近在其2a期临床试验中达到了LPLV（最后一名患者最后一次访视），标志着一个重要的里程碑。RN-014是一种小分子治疗候选药物，通过使用iPS细胞衍生的ADPKD疾病模型进行筛选而确定，目前正在进行2a期临床试验数据的分析。

In addition, RN-032, an iPS cell-derived regenerative medicine program based on renal nephron progenitor cells, has completed process development in preparation for nonclinical studies and is progressing to the next stage.

此外，基于肾单位祖细胞的iPS细胞衍生再生医学项目RN-032已完成工艺开发，为非临床研究做好准备，并正推进至下一阶段。

The financing will support continued advancement of these core programs while strengthening the company's long-term growth strategy.

此次融资将支持这些核心项目的持续推进，同时强化公司的长期增长战略。

Future Strategy and Use of Proceeds

未来战略及资金用途

The capital raised will be allocated across four key priorities:

所筹集的资金将分配至四个关键优先事项：

1. RN-014 Commercialization and Global Licensing Activities

1. RN-014 商业化与全球许可活动

Building on insights generated from the Phase 2a clinical trial, Rege Nephro plans to pursue global licensing and partnering opportunities for RN-014 while continuing development activities aimed at further evaluating the program's therapeutic potential.

基于从2a期临床试验中获得的见解，Rege Nephro计划寻求RN-014的全球许可和合作机会，同时继续开展旨在进一步评估该治疗方案潜力的开发活动。

2. Supporting Nonclinical Development of RN-032

2. 支持 RN-032 的非临床开发

Following the completion of process development for RN-032, the company will advance RN-032 into nonclinical studies to establish the foundation for future clinical trials.

在完成RN-032的工艺开发后，公司将推进RN-032进入非临床研究阶段，为未来的临床试验奠定基础。

3. Expanding Discovery Research and Kidney Regeneration Programs

3. 拓展探索性研究与肾脏再生项目

The company will continue to invest in discovery and translational research, including next-generation kidney regeneration technologies and future pipeline candidates. Rege Nephro ultimately aims to develop therapies that improve outcomes and quality of life for patients with kidney disease while reducing progression to kidney failure..

该公司将继续投资于发现性研究和转化研究，包括下一代肾脏再生技术和未来管线候选药物。Rege Nephro 的最终目标是开发能够改善肾病患者预后和生活质量、同时减缓向肾衰竭进展的疗法。

4. Strengthening Organizational Capabilities

4. 加强组织能力

To support continued growth, Rege Nephro plans to expand its team by recruiting scientific, clinical development, and business development professionals with specialized expertise.

为支持持续增长，Rege Nephro 计划通过招聘具有专业专长的科学、临床开发和业务发展专业人士来扩大其团队。

Through this financing, Rege Nephro seeks to advance its pipeline while strengthening the operational foundation required to support future growth and long-term value creation.

通过此次融资，Rege Nephro旨在推进其研发管线，同时夯实支持未来增长和长期价值创造所需的运营基础。

List of the investors

投资者名单

(In alphabetical order)

（按字母顺序排列）

Arcus South East Asia

阿库斯东南亚

BA7 Venture Capital CORP

BA7 风险投资公司

Chushin Venture Capital Co., Ltd.

初信创业投资有限公司

DCI Partners Co., Ltd.

DCI Partners有限公司

JAFCO Group Co., Ltd.

杰富仕集团股份有限公司

JIC Venture Growth Investments Co., Ltd.

JIC创业成长投资有限公司

Kyoshin Social Capital Co., Ltd.

京震社会资本有限公司

Kyoto University Innovation Capital Co., Ltd.

京都大学创新资本有限公司

Mitsubishi UFJ Capital Co., Ltd.

三菱UFJ资本株式会社

RAP-HI Co., Ltd.

RAP-HI有限公司

SPARX Asset Management Co., Ltd.

SPARX资产管理有限公司

TaiAn Technologies Corp.

泰安科技有限公司

TOHO HOLDINGS CO., LTD.

东宝控股株式会社

Comment from Akifumi Morinaka, Representative Director and CEO of Rege Nephro:

Rege Nephro 代表董事兼首席执行官森中章文的评论：

'This funding round marks an important milestone as we advance RN-014 toward commercialization and accelerate development of RN-032,' said Akifumi Morinaka, Representative Director and CEO of Rege Nephro. 'I would like to express my sincere gratitude to our investors for their support and confidence in our vision and progress.

Rege Nephro的代表董事兼首席执行官森中章夫表示：“本轮融资标志着一个重要的里程碑，因为我们正在推动RN-014迈向商业化，并加速RN-032的开发。我要向我们的投资者表示衷心的感谢，感谢他们对我们愿景和进展的支持与信任。”

With RN-014 having completed its Phase 2a clinical trial and RN-032 advancing toward its next stage of development, we believe the company is well positioned for continued growth. We remain committed to addressing unmet medical needs in kidney disease through innovative medicines and regenerative therapies based on iPS cell technology.'.

随着RN-014完成IIa期临床试验，且RN-032推进至下一开发阶段，我们认为公司已为持续增长奠定良好基础。我们仍致力于通过基于诱导多能干细胞（iPS细胞）技术的创新药物和再生疗法，满足肾脏疾病领域尚未被满足的医疗需求。

About Rege Nephro Co., Ltd.

关于瑞格肾科有限公司

Rege Nephro Co., Ltd. is a clinical-stage biotechnology company that leverages scientific discoveries originating from the research of Professor Kenji Osafune at Kyoto University's Center for iPS Cell Research and Application (CiRA).

Rege Nephro有限公司是一家临床阶段的生物技术公司，依托于京都大学iPS细胞研究与应用中心（CiRA）的Kenji Osafune教授的研究成果所衍生的科学发现。

The company is developing innovative therapies for kidney diseases based on iPS cell technology, with the goal of expanding treatment options for patients with serious and difficult-to-treat conditions.

该公司正基于诱导多能干细胞（iPS细胞）技术开发针对肾脏疾病的创新疗法，旨在为患有严重且难治性疾病的患者拓展治疗选择。

URL:

网址：

https://www.regenephro.co.jp/en

https://www.regenephro.co.jp/zh

SOURCE Rege Nephro Co., Ltd.

来源：瑞格肾病有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示